Recent Prospectives of Anticancer Histone Deacetylase Inhibitors
Histone deacetylases (HDACs) are common targets for cancer therapy as they are expressed in many forms of cancers; several research studies have been introduced discussing the design of small molecules that target this abnormal epigenetic changes developed by HDACs in chromatin. In the past 10 years, HDAC inhibitors have emerged as important agents of interest in clinical trials for several ... Read more